Nasus Pharma Ltd. (NYSE: NSRX) announced a USD 15.0 million private placement financing on February 10, 2026, targeting the advancement of its intranasal pharmaceutical development pipeline. The Tel Aviv-based clinical-stage pharmaceutical company will close the transaction on or about February 12, 2026, with proceeds designated to fund the pivotal clinical development of NS002 for anaphylaxis treatment, initiate first-in-human studies for additional pipeline assets, and support general corporate operations.
The Nasus Pharma financing includes the sale of 2,695,425 ordinary shares and accompanying warrants at a combined purchase price of USD 5.565 per share. The warrants, exercisable at USD 6.53 per share, will expire upon the earlier of two years from issuance or 30 trading days following the top-line results announcement of the NS002 pivotal study. Citizens Capital Markets served as the lead placement agent, with Laidlaw & Company (UK) Ltd. acting as co-placement agent. The private placement attracted participation from both new and existing institutional investors, including certain members of the company's Board of Directors.
Company Overview and Pipeline
Nasus Pharma operates as a clinical-stage pharmaceutical company specializing in intranasal powder product development for acute medical conditions. The company's lead asset, NS002, represents an intranasal powder epinephrine product candidate designed as a needle-free alternative to traditional epinephrine autoinjectors for anaphylaxis treatment. The proprietary powder-based intranasal (PBI) technology leverages the nasal cavity's vascular network, utilizing uniform spherical powder particles to potentially achieve faster and more reliable drug delivery compared to liquid-based nasal products.
The NS002 program is currently advancing through pivotal clinical development, with upcoming milestones including the anticipated top-line results from the Phase II/III study. Additional pipeline assets are under investigation, though specific details remain limited. The company's technological approach centers on creating needle-free, easy-to-use alternatives for rapid drug administration, with a particular focus on leveraging intranasal delivery mechanisms for acute medical interventions.